| DRG | Dorsal Root Ganglia |
|---|---|
| DRG | diagnosis-related group; Division of Research Grants [NIH}; dorsal respiratory group; dorsal root ga... |
| drg | drainage |
| PM-DRG | pediatric modified diagnosis-related group |
| AN-DRG | Australian National Diagnosis Related Group |
|---|---|
| DRG | Diagnosis Related Group |
| DRG | Diagnostic Related Group |
| DRG | Dorsal Root Ganglia |
| DRG | Dorsal Root Ganglion |
| famotidine | <chemical> 3-(((2-((aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-n-(aminosulfonyl)propanimidamide. A competitive histamine h2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion. The drug does not affect cardiovascular, renal, endocrine, pancreatic exocrine, or gastrointestinal motility functions. No clinically important interactions with other drugs have been described. It is an effective agent in the therapy of duodenal, gastric, and peptic ulcer, as well as of zollinger-ellison syndrome. Pharmacological action: anti-ulcer agents, histamine h2 antagonists. Chemical name: Propanimidamide, 3-(((2-((aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulfonyl)- (12 Dec 1998) |
|---|---|
| DRG | <abbreviation> Diagnosis-related group. (05 Mar 2000) |
| outliers, drg | In health care reimbursement, especially in the prospective payment system, those patients who require an unusually long hospital stay or whose stay generates unusually high costs. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|